Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
DEA proposes temporary Schedule I placement for three kratom derivatives (mitragynine pseudoindoxyl, MGM-15, MGM-16), making them illegal to manufacture, distribute, or possess without DEA registration.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, API suppliers, compounders, and distributors handling or considering these substances should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective upon publication in Federal Register (expected within days); 30-day comment period. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Three substances are being temporarily placed in Schedule I, prohibiting all non-research activities
Who it affects
All pharmaceutical manufacturers, API suppliers, compounders, and distributors handling or considering these substances
What you must do
Cease all manufacturing, distribution, and dispensing of these substances; destroy or surrender existing stocks per DEA guidance
Deadline
Effective upon publication in Federal Register (expected within days); 30-day comment period
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness